United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - letrozole - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - letrozole - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk) ltd - letrozole - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - letrozole - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - letrozole - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - letrozole - oral tablet - 2.5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.  letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see clinical studies ( 14.2, 14.3)] . letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy 

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see clinical studies (14.2, 14.3)] . letrozole tablets  are  indicated  for  first-line   treatment  of   postmenopausal  women  with  hormone  receptor  positive  or  unknown,   locally  advanced  or  metastatic  breast   cancer.  letrozole tablets  are also  indicated  for  the   treatment  of  advanced  breast   cancer  in  postmenopausal   women  with  disease  progression  following  antiestrogen  therapy  [see  clinical  studies  (14.4,  14.5)]. - pregnancy: letrozole can   caus